Tight Glycemic Control: Critical Care’s Balancing Act
Executive Summary
Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving patient outcomes. Today, a small pack of companies is trying to finally deliver on the promise.
You may also be interested in...
Research Briefs: HeartWare Adds Patients To ENDURANCE; GlySure ICU Glucose Trial; Biotronik Home Monitoring
FDA has approved HeartWare’s plan to add more patients to the ENDURANCE trial of its HVAD ventricular assist device as a destination therapy for patients with end-stage heart failure. Results of a pilot trial of GlySure’s continuous glucose monitoring system were presented at a conference in South Africa. More research.
FDA Wants To See New, Improved Hospital Continuous Glucose Monitors
FDA is encouraging industry to submit study designs for newer, more accurate continuous glucose monitors for hospital use. It gathered experts at a June 25 public meeting to discuss questions around indications for use and trial designs.
Cautious FDA Is Obstacle For Burgeoning Diabetes Device Market
Is innovation in the diabetes device market being hampered by a slowdown in FDA approvals? That question was the unofficial, under-riding theme at the American Diabetes Association 71st Scientific Sessions in June.